Role of nitric oxide following cardiac transplantation

Journal of Human Hypertension

Volumn 12, Issue 12, 1998, Pages 833-837

  Chester, A H ^a   Birks, E J ^a   Yacoub, M H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Nitric oxide; Transplantation

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

CORONARY ARTERY DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; MYOCARDIAL DISEASE; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; REVIEW; THROMBOEMBOLISM;

EID: 0032436672     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000735     Document Type: Review

References (71)

1. Moncada S. The 1991 Ulf von Euler Lecture. The L-arginine: nitric oxide pathway. Acta Physiol Scand 1992; 145: 201-227.
2. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994; 343: 1199-1206.
3. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994; 120: 227-237.
4. Mitchell JA, Sheng H, Forstermann U, Murad F. Characterization of nitric oxide synthases in non-adrenergic non-cholinergic nerve containing tissue from the rat anococcygeus muscle. Br J Pharmacol 1991; 104: 289-291.
5. Pollock JS et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-10484.
6. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 682-685.
7. Chester AH et al. Induction of nitric oxide synthase in human vascular smooth muscle: interactions between proinflammatory cytokines. Cardiovasc Res 1998; 38: 814-821.
8. Vane JR et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-2050.
9. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
10. Steuhr DJ, Cho HJ, Wise NS, Nathan C. Purification and characterisation of the cytokine induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci USA 1991; 88: 7773-7777.
11. Birks EJ, Yacoub MH. The role of nitric oxide and cytokines in heart failure. Coronary Artery Dis 1997; 8: 389-402.
12. Brady AJB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992; 263: H1963-H1966.
13. Evans HG, Lewis MJ, Shah AM. Interleukin-1B modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res 1993; 27: 1486-1490.
14. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994; 89: 2070-2078.
15. Grocott-Mason R, Fort S, Lewis MJ, Shah AM. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol 1994; 266: H1699-H1705.
16. Chester AH et al. The role of nitric oxide in mediating endothelium dependent relaxations in the human epicardial coronary artery. Int J Cardiol 1990; 29: 305-309.
17. Laurent S et al. The arterial wall: A new pharmacological and therapeutic target. Fundam Clin Pharmacol 1996; 10: 243-257.
18. Worrall NK et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 181: 63-70.
19. Worrall NK et al. Inhibition of inducible nitric oxide synthase ameliorates functional and histological changes of acute lung allograft rejection. Transplantation 1997; 63: 1095-1101.
20. Winlaw DS et al. Increased nitric oxide production in heart failure. Lancet 1994; 344: 373-374.
21. Habib F et al. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet 1994; 344: 371-373.
22. Yang X et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994; 94: 714-721.
23. Habib FM et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347: 1151-1155.
24. Fish RD et al. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest 1988; 81: 21-31.
25. Lau DC, Wong KL, Hwang WS. Cyclosporine toxicity on cultured rat microvascular endothelial cells. Kidney Int 1989; 35: 604-613.
26. Shears LL et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997; 100: 2035-2042.
27. Koglin J, Glysing-Jensen T, Mudgett JS, Russell ME. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 1998; 97: 2059-2065.
28. Ravalli S et al. Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease. Circulation 1998; 97: 2338-2345.
29. Baker CS et al. Cycooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and co-distributes with inducible nitric oxide synthase and nitrityrosine particularly in macrophages. Arterioscler Thromb Vase Biol 1998; (In press)
30. Langrehr JA, White DA, Hoffman BS, Simmons MD. Macrophages produce nitric oxide at allograft sites. Annals of Surgery 1993; 218: 159-166.
31. Faller DV, Barnett H, Weisbrod R, Cohen RA. Regulation of nitric oxide synthase induction in cultured vascular smooth muscle cells by lipopolysaccharide and Interferon. Endothelium 1996; 4: 99-112.
32. Worrall NK et al. Inhibition of inducible nitric oxide synthase attenuates established acute cardiac allograft rejection. Ann Thorac Surg 1996; 62: 378-385.
33. Winlaw DS et al. Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 1995; 60: 77-82.
34. Langrehr JM et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679-683.
35. Green LC et al. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981; 78: 7764-7768.
36. Tanaka S et al. Evaluation of nitric oxide during acute rejection after heart transplantation in rats. Transplant Proc 1995; 27: 576-577.
37. Winlaw DS et al. Urinary nitrate excretion is a noninvasive indicator of acute cardiac allograft rejection and nitric oxide production in the rat. Transplantation 1994; 58: 1031-1036.
38. Benvenuti C, Bories PN, Loisance D. Increased serum nitrate concentration in cardiac transplant patients. A marker for acute allograft cellular rejection. Transplantation 1996; 61: 745-749.
39. Mugge A et al. Urinary nitrate excretion is increased in cardiac transplanted patients with acute graft rejection. Clin Transplant 1996; 10: 298-305.
40. Lewis NP et al. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 1996; 93: 720-729.
41. Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. Transplant Proc 1991; 23: 3260-3261.
42. Cai B et al. Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection. Int J Cardiol 1995; 50: 243-251.
43. Worrall NK et al. Corticosteroids inhibit expression of inducible nitric oxide synthase during acute cardiac allograft rejection. Transplantation 1996; 61: 324-328.
44. Valantine HA et al. Doppler echocardiographic indices of diastolic function as markers of acute cardiac rejection. Transplant Proc 1987; 19: 2556-2559.
45. Valantine HA et al. A hemodynamic and Doppler echocardiographic study of ventricular function in long-term cardiac allograft recipients. Etiology and prognosis of restrictive-constrictive physiology. Circulation 1989; 79: 66-75.
46. Paulsen W et al. Left ventricular function of heart allografts during acute rejection: an echocardiographic assessment. J Heart Transplant 1985; 4: 525-529.
47. Stevenson LW, Lewis W, MacAlpin RN, Clark S. Acute reversible cardiogenic shock: immune-mediated with mild histologic change. Am Heart J 1986; 111: 611-613.
48. Worrall NK et al. Inflammatory cell-derived NO modulates cardiac allograft contractile and electrophysiological function. Am J Physiol 1997; 273: H28-H37.
49. Ziolo MT, Dollinger SJ, Wahler GM. Myocytes isolated from rejecting transplanted rat hearts exhibit reduced basal shortening which is reversible by aminoguanidine. J Mol Cell Cardiol 1998; 30: 1009-1017.
50. Johnson MR. Transplant coronary disease: non-immunological risk factors. J Heart Lung Transplant 1992; 11: S124-S132.
51. Weis M, Von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069-2077.
52. Drexler H et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology. Circulation 1994; 89: 1615-1623.
53. Kushwaha S et al. Substance P for evaluation of coronary endothelial function after cardiac transplantation. J Am Coll Cardiol 1991; 17: 1537-1544.
54. Kushwaha S et al. Coronary endothelial function in cardiac transplant recipients with accelerated coronary disease. Coronary Artery Dis 1994; 5: 147-154.
55. Mugge A et al. Endothelial dysfunction in heart transplanted patients with graft vasculopathy. Eur Heart J 1995; 16: 78-83.
56. Weis M et al. Variations of segmental endothelium-dependent and endothelium-independent vasomotor tone after cardiac transplantation (qualitative changes in endothelial function). Am Heart J 1997; 134: 306-315.
57. Berkenboom G et al. Endothelial function of internal mammary artery in patients with coronary artery disease and in cardiac transplant recipients. Am Heart J 1998; 135: 488-494.
58. Pinsky DJ et al. Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest 1994; 93: 2291-2297.
59. Hamilton DV, Carmichael DJS, Evans DB, Calne RY. Hypertension in renal transplant recipients on cyclosporin A and corticosteroids and azathioprine. Transplant Proc 1982; 14: 597-600.
60. Sweny P, Hopper J, Gross M, Varghese Z. Nephrotoxicity of cyclosporin A. Lancet 1981; 1: 663-664.
61. Neild GH, Reuben R, Hartley RB, Cameron JS. Glomerular thrombi in renal allografts associated with cyclosporine treatment. J Clin Pathol 1985; 38: 253-258.
62. Vassalli G, Gallino A. Endothelial dysfunction and accelerated coronary artery disease in cardiac transplant recipients. Eur Heart J 1997; 18: 1712-1717.
63. Sudhir K et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994; 90: 3018-3023.
64. Diederich D, Yang Z, Luscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992; 2: 1291-1297.
65. Bossaller C et al. Cyclosporin A inhibits endothelium-dependent vasodilation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165-169.
66. Dinh Xuan AT, Fan TPD, Higenbottam TW, Wallwork J. Cyclosporin in vitro reduces endothelium-dependent relaxation to acetylcholine but does not effect relaxation to nitrovasodilators. Transplant Proc 1990; 22: 1723-1725.
67. Richards NT, Poston L, Hilton PJ. Cyclosporine A inhibits endothelium-dependent, prostanoid-induced relaxation in human subcutaneous resistance vessels. J Hypertens 1989; 8: 159-163.
68. Mankad P et al. Acute effects of cyclosporine and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat heart. Cardiovasc Drugs Ther 1992; 6: 77-83.
69. O'Neil GS et al. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br Heart J 1991; 66: 212-216.
70. O'Neil GS et al. The effect of cyclosporine on the release of endothelium-derived relaxing factor from isolated human epicardial coronary arteries. Transplantation 1991; 51: 736-738.
71. Stroes ES et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997; 29: 570-575.